BOSTON & LYON, France--(BUSINESS WIRE)--Regulatory News:
ERYTECH Inc., the US affiliate of ERYTECH Pharma (Euronext Paris: ERYP) (Paris:ERYP) (ADR:EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the appointment of Iman El-Hariry as Chief Medical Officer, responsible for global medical, clinical and regulatory affairs.
Help employers find you! Check out all the jobs and post your resume.
ERYTECH Inc., the US affiliate of ERYTECH Pharma (Euronext Paris: ERYP) (Paris:ERYP) (ADR:EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the appointment of Iman El-Hariry as Chief Medical Officer, responsible for global medical, clinical and regulatory affairs.
Help employers find you! Check out all the jobs and post your resume.
